Malaria on the decline
10 December, 2014Good news: the number of people dying from malaria has fallen dramatically since 2000, according to the World Malaria Report 2014.
Biotron completes recruitment for BIT225 trial
04 December, 2014 by Dylan Bushell-EmblingBiotron (ASX:BIT) has enrolled all 60 patients for a Thai phase II trial of BIT225 in HCV genotypes 1 or 3.
New brain cancer treatment on trial
04 December, 2014Collaborative research carried out for more than a decade will be funnelled into a clinical trial on a treatment for brain cancer.
Imugene to divest drug delivery platform
02 December, 2014 by Dylan Bushell-EmblingImugene has announced plans to divest its drug delivery platform linguet and revealed more promising preclinical data from its HER-Vaxx immuno-oncology program.
Virax appoints three new board members
01 December, 2014 by Dylan Bushell-EmblingVirax (ASX:VHL) has named a new non-executive chairman and two new non-executive directors to help support the clinical development of its oncology portfolio.
Novogen identifies lead anti-tropomyosin drug
24 November, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has selected the lead candidate from its family of drugs designed to complement existing chemotherapies by targeting a different part of a cancer's cytoskeleton.
Novogen chair-elect steps down suddenly
20 November, 2014 by Dylan Bushell-EmblingIain Ross, the director due to replace Dr Graham Kelly as chairman of the board of Novogen (ASX:NRT), has stepped down suddenly citing an unanticipated conflict of interest.
Funding dementia research
19 November, 2014The Alzheimer's Australia Dementia Research Foundation will award grants and fellowships worth $2.4 million to 25 early-career researchers.
Reducing salt prevents kidney failure
18 November, 2014Reducing salt intake can reduce the warning signs of higher urinary albumin that is indicative of kidney and heart disease.
Viralytics wins nod for phase I Cavatak trial
17 November, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has secured approval for a phase I trial of Cavatak in non-muscle invasive bladder cancer, to be conducted in the UK in the first quarter of 2015.
Novogen CEO to hand over chairman role
12 November, 2014 by Dylan Bushell-EmblingWith Novogen (ASX:NRT) moving to take anticancer candidate Cantrixil into the clinic, the company is making moves to line up funding and allow it to better focus on clinical development.
Cavatak combines with immune checkpoint inhibitors
10 November, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) said preclinical data suggests that its Cavatak anticancer candidate performs better when combined with immune checkpoint inhibitors.
Patrys postpones PAT-SM6 trial
07 November, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has advised that complications in the manufacturing process are likely to delay the commencement of a planned trial of PAT-SM6 in multiple myeloma until 2Q15.
Potential new approach to treating diabetes
07 November, 2014Regulating beta cell stress provides a potential new approach to treating diabetes.
Prima's CVac improves OS in ovarian cancer trial
06 November, 2014 by Dylan Bushell-EmblingPrima BioMed's (ASX:PRR) CVac candidate is demonstrating a clear trend in improved overall survival in patients with second remission ovarian cancer.
